ELICIO THERAPEUTICS, INC. ELTX 深 滬
等待開盤 10-29 09:30:00 美东时间
9.74
+0.040
+0.41%
華盛通- 最 高10.16
- 今 開9.98
- 成交量 7.73万股
- 最 低 9.6101
- 昨 收 9.70
- 總市值 1.59亿
- 52周最高 12.62
- 市盈率 靜 --
- 換手率 0.47%
- 52周最低 4.60
- 委 比 -71.43%
- 總股本 1633.83万
- 歷史最高 263.00
- 量 比 0.77
- 振 幅 5.67%
- 歷史最低 2.96
- 每 手 1
- 風險率 2.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Elicio Therapeutics Announced That Preliminary Analysis Of Patients In The Ongoing Phase 2 AMPLIFY-7P Trial Indicated That Specific Human Leukocyte Antigen Types; ELI-002 7P Shows Broad T-Cell Response Against mKRAS-Mutated Cancers Across Diverse Patient HLA Types
ELI-002 7P demonstrated robust mKRAS-specific T cell responses across a broad range of HLA types, highlighting its potential for use among a diverse patient populationPatients treated with ELI-002 7P represented a
10-27 20:22
Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial
Elicio Therapeutics announced preliminary results from its Phase 2 AMPLIFY-7P trial showing ELI-002 7P induced robust mKRAS-specific T cell responses across a diverse HLA population. Among 89 patients, 1,132 unique HLA types were identified, with 99% of patients (88/89) developing mKRAS-specific T cell responses. These findings suggest ELI-002 7P may benefit a broad spectrum of pancreatic ductal adenocarcinoma (PDAC) patients, addressing a critic...
10-27 12:00
Elutia Announces Closing of BioEnvelope Business Sale to Boston Scientific Corporation for $88 Million
Elutia Inc. sold its BioEnvelope business to Boston Scientific for $88 million and plans to use the proceeds to develop and launch NXT-41x, a biomatrix targeting mastectomy reconstruction infections. The product aims to reduce complications in breast reconstruction, a $1.5 billion U.S. market. Elutia expects to bring NXT-41x to market by mid-2027.
10-01 12:41
Elicio Therapeutics Announces Planned Initiation Of Investigator-Initiated Phase 1 Trial Of ELI-002 7P In Combination With Chemotherapy And Anti-PD1 Checkpoint Inhibitor In Borderline And Resectable PDAC
Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor ("CPI") in the neoadjuvant setting Trial is anticipated to begin enrolling in H1'2026 BOSTON, Sept. 29, 2025 (GLOBE
09-29 20:19
Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
Elicio Therapeutics plans to initiate a Phase 1 neoadjuvant study of ELI-002 7P, an investigational AMP cancer vaccine targeting KRAS-driven cancers, in combination with chemotherapy (mFOLFIRINOX) and an anti-PD-1 checkpoint inhibitor for pancreatic ductal adenocarcinoma (PDAC). The investigator-initiated trial, led by Dr. Kevin Soares of Memorial Sloan Kettering Cancer Center and funded by the Lustgarten Foundation, aims to enroll 20 patients ac...
09-29 12:00
Elicio Therapeutics Reports Inducement Grants
Elicio Therapeutics granted 9,800 inducement stock options to two new employees on September 15, 2025, priced at $10.08 per share, vesting over four years. The company, focusing on novel immunotherapies for high-prevalence cancers, is advancing its lead program ELI-002, an off-the-shelf vaccine targeting KRAS mutations, with promising data from Phase 1 studies in pancreatic and colorectal cancers. Elicio plans to expand ELI-002 to other indicatio...
09-18 12:00
Elicio's ELI-002 Triggers mKRAS-Specific T Cell Responses In 99% Of Phase 2 AMPLIFY-7P Trial Patients
ELI-002 induced mKRAS-specific T cell responses in 99% of evaluable patients (89 of 90) who were treated with the investigational vaccine immunotherapyRobust mKRAS-specific T cell responses were observed with an average
09-17 20:08
Elite Express Holding Inc. Announces Pricing of $15.2 Million Initial Public Offering
Elite Express Holding Inc. (ETS) announced the pricing of its initial public offering of 3,800,000 shares of Class A common stock at $4.00 per share, with total gross proceeds of approximately $15.2 million. The offering included an option for underwriters to purchase an additional 570,000 shares. ETS's shares will begin trading on the Nasdaq Capital Market under the ticker "ETS" on August 21, 2025, and the offering is expected to close on August...
08-20 23:53
美股牛股 | 迅雷绩后上演翻倍行情！投资影石创新浮盈超50亿；OpenDoor隔夜大涨19%
迅雷绩后上演翻倍行情！投资影石创新浮盈超50亿；OpenDoor隔夜大涨19%，此前获知名加密货币投资者买入>>
08-19 19:53
Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients
Elicio Therapeutics reported promising results from the Phase 1 AMPLIFY-201 study of ELI-002, a mutant KRAS (mKRAS)-targeting vaccine, in patients with pancreatic and colorectal cancers. The study showed a significant improvement in overall survival (OS) from 16.33 to 28.94 months, alongside a 77% reduction in the risk of death and an 88% reduction in the risk of relapse. ELI-002 induced robust T cell responses, particularly CD4+ and CD8+ mKRAS-s...
08-12 12:00
